1421 (1421) Fair Value & Analysis

Technology · Market cap HK$79.1M

1 1421 1421 · HK

PriceHK$0.3950

Fair ValueHK$0.2866

Upside-27.4%

Quality37/100

Watch 1421 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$0.1589 – HK$0.3953

Fair value as of: Jul 2, 2026

From 3 valuation models · updated today

Share price −4.9% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.3393 – HK$0.7394 · fair‑value band HK$0.1589 – HK$0.3953 · the HK$0.3950 price screens above the HK$0.2866 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1421 (1421) currently trades at HK$0.3950, while our model-based Fair Value estimate is HK$0.2866 — implying the stock looks roughly 27.4% overvalued today. We read business quality at 37/100 (below-average quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 1421 generated revenue of HK$145M at a net margin of -11.6%. Revenue grew 3.6% year over year. It earns a return on equity of -11.2%. Net debt stands at HK$4.0M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$145M

Revenue growth (YoY) +3.6%

Net margin -11.6%

Return on equity -11.2%

Free cash flow −HK$18.7M FY2025

Operating margin -21.8%

More key figures

EPS (TTM) HK$-0.0400

Net debt HK$4.0M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1421 reported revenue of HK$143M in FY2025 versus HK$380M in FY2021, a compound −21.7%/yr. Reported net income was −HK$21.8M in FY2025.

Revenue −21.7%/yr

FY21 HK$380M

FY22 HK$212M

FY23 HK$81.5M

FY24 HK$161M

FY25 HK$143M

Net income

FY21 −HK$30.1M

FY22 −HK$44.0M

FY23 −HK$61.6M

FY24 −HK$47.3M

FY25 −HK$21.8M

Is 1421 fairly valued? → Check now

Similar stocks

6 more Solar stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
First Solar, Inc FSLR	$263.11	$284.45	+8%
Nextpower Inc NXT	$131.57	$79.08	-40%
Waaree Energies Limited WAAREEENER	₹3,053	₹4,337	+42%
Tongwei Co 600438	¥13.00	¥47.50	+265%
Enphase Energy, Inc ENPH	$50.57	$20.83	-59%
Jinko Solar Co 688223	¥5.15	¥7.41	+44%

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1421 (1421) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.2866 versus a price of HK$0.3950 — about −27% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1421?

Our model-based fair value for 1421 is HK$0.2866 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.3950.

What is the quality score of 1421?

1421 has a Quality Score of 37/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1421 (1421)?

1421 reported trailing-twelve-month revenue of about HK$145M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1421?

The net profit margin of 1421 is about -11.6%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.